Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL MHR PHARMA : revenue, balance sheet and financial ratios

SPFPL MHR PHARMA is a French company founded 14 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in COURBEPINE (27300), this company of category PME shows in 2021 a net income positive of 768 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL MHR PHARMA (SIREN 750577660)
Indicator 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C
Net income 768 385 € -57 510 € 83 833 € 73 046 € 75 847 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2021, SPFPL MHR PHARMA generates positive net income of 768 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2021: 76 k€ -> 768 k€.

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

768 385 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 195%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

195.403%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

33.732%

Solvency indicators evolution
SPFPL MHR PHARMA

Sector positioning

Debt ratio
195.4 2021
2019
2020
2021
Q1: 0.02
Med: 12.01
Q3: 99.49
Average

In 2021, the debt ratio of SPFPL MHR PHARMA (195.40) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
33.73% 2021
2019
2020
2021
Q1: 18.1%
Med: 61.65%
Q3: 91.15%
Average -10 pts over 3 years

In 2021, the financial autonomy of SPFPL MHR PHARMA (33.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 2399.53. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

2399.535

Liquidity indicators evolution
SPFPL MHR PHARMA

Sector positioning

Liquidity ratio
2399.53 2021
2019
2020
2021
Q1: 111.19
Med: 514.23
Q3: 3099.95
Good +40 pts over 3 years

In 2021, the liquidity ratio of SPFPL MHR PHARMA (2399.53) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positioning of SPFPL MHR PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 4 503 335€ to 14 101 322€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2021
Indicative
4503k€ 11504k€ 14101k€
11 504 491 € Range: 4 503 335€ - 14 101 322€
NAF 5 année 2021

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL MHR PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL MHR PHARMA

What is the revenue of SPFPL MHR PHARMA ?

The revenue of SPFPL MHR PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL MHR PHARMA profitable?

Yes, SPFPL MHR PHARMA generated a net profit of 768 k€ in 2021.

Where is the headquarters of SPFPL MHR PHARMA ?

The headquarters of SPFPL MHR PHARMA is located in COURBEPINE (27300), in the department Eure.

Where to find the tax return of SPFPL MHR PHARMA ?

The tax return of SPFPL MHR PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL MHR PHARMA operate?

SPFPL MHR PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.